Metabolic syndrome as a pathophysiological modifier in polycythemia vera

Current understanding

Metabolic syndrome co-occurring with polycythemia vera appears to amplify systemic oxidative stress beyond PV alone, with case-control data showing higher total oxidant status in PV+MetS versus PV without MetS. This suggests MetS is not merely a comorbidity but a candidate pathophysiological modifier of PV, plausibly acting through shared redox and inflammatory axes that could compound vascular risk.

Evidence log

• 2026-07-13 — Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.: cross-connection with thrombosis-risk: Cardiovascular risk factors independently drive thrombotic risk in triple-negative ET, reinforcing cardiometabolic substrate as a thrombosis modifier distinct from clonal/driver biology. (novelty: 3)
• 2026-06-19 — Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think?: cross-connection with oxidative-stress-mpn: Oxidative stress (TOS) is the measured axis linking metabolic syndrome to worsened PV pathophysiology. (novelty: 3)

Open questions

Related